Mutations with Epigenetic Effects in Myeloproliferative Neoplasms and Recent Progress in Treatment: Proceedings from the 5th International Post-ASH Symposium

DSpace/Manakin Repository

Mutations with Epigenetic Effects in Myeloproliferative Neoplasms and Recent Progress in Treatment: Proceedings from the 5th International Post-ASH Symposium

Citable link to this page

. . . . . .

Title: Mutations with Epigenetic Effects in Myeloproliferative Neoplasms and Recent Progress in Treatment: Proceedings from the 5th International Post-ASH Symposium
Author: Tefferi, A; Abdel-Wahab, O; Cervantes, F; Crispino, J D; Finazzi, G; Girodon, F; Gisslinger, H; Gotlib, J; Kiladjian, J-J; Licht, J D; Odenike, O; Pardanani, A; Silver, R T; Solary, E; Mughal, T; Mullally, Ann; Levine, R L

Note: Order does not necessarily reflect citation order of authors.

Citation: Tefferi, A.O., Abdel-Wahab, F. Cervantes, J.D. Crispino, G. Finazzi, F. Girodon, H. Gisslinger, et al. 2011. Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: proceedings from the 5th international post-ash symposium. Blood Cancer Journal 1(3): e7.
Full Text & Related Files:
Abstract: Immediately following the 2010 annual American Society of Hematology (ASH) meeting, the 5th International Post-ASH Symposium on Chronic Myelogenous Leukemia and BCR-ABL1-Negative Myeloproliferative Neoplasms (MPNs) took place on 7–8 December 2010 in Orlando, Florida, USA. During this meeting, the most recent advances in laboratory research and clinical practice, including those that were presented at the 2010 ASH meeting, were discussed among recognized authorities in the field. The current paper summarizes the proceedings of this meeting in BCR-ABL1-negative MPN. We provide a detailed overview of new mutations with putative epigenetic effects (TET oncogene family member 2 (TET2), additional sex comb-like 1 (ASXL1), isocitrate dehydrogenase (IDH) and enhancer of zeste homolog 2 (EZH2)) and an update on treatment with Janus kinase (JAK) inhibitors, pomalidomide, everolimus, interferon-α, midostaurin and cladribine. In addition, the new ‘Dynamic International Prognostic Scoring System (DIPSS)-plus' prognostic model for primary myelofibrosis (PMF) and the clinical relevance of distinguishing essential thrombocythemia from prefibrotic PMF are discussed.
Published Version: doi:10.1038/bcj.2011.4
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255279/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:8603493

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters